• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Sanofi-Aventis ADR

Sanofi-Aventis ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Disease Type 1

    European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Disease Type 1

  2. INVESTOR ALERT: Class Action Lawsuit Against Sanofi Announced by Law Offices of Howard G. Smith

    INVESTOR ALERT: Class Action Lawsuit Against Sanofi Announced by Law Offices of Howard G. Smith

  3. Shareholder Alert: Pomerantz Law Firm Announces the Filing of a Class Action against Sanofi and Certain Officers - SNY

    Shareholder Alert: Pomerantz Law Firm Announces the Filing of a Class Action against Sanofi and Certain Officers - SNY

  4. UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015

    UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015

  5. Rentrak Announces Official Worldwide Box Office Results for Weekend of January 18, 2015

    Rentrak Announces Official Worldwide Box Office Results for Weekend of January 18, 2015

  6. Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

    Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

  7. Rentrak Announces Official Worldwide Box Office Results for Weekend of January 11, 2015

    Rentrak Announces Official Worldwide Box Office Results for Weekend of January 11, 2015

  8. Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

    Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

  9. Rentrak Announces Official Worldwide Box Office Results for Weekend of January 4, 2015

    Rentrak Announces Official Worldwide Box Office Results for Weekend of January 4, 2015

  10. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.